The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database.

OBJECTIVES To describe the use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA) and changing trends in their use. METHODS We used the General Practice Research Database (GPRD) to describe DMARD use by patients with RA identified using ICD-9 codes. The GPRD is a UK national database containing records of more than 7 million individuals from 683 general practices. Subjects were studied between 1987 and 2002. The prevalence and duration of individual DMARD use and changing trends in DMARD use were investigated. RESULTS Thirty-four thousand three hundred and sixty-four patients with RA were identified. Only 17,115 (50%) individuals were prescribed at least one DMARD during the study period. The most commonly prescribed DMARD over the study period was sulphasalazine (46.3%) and then methotrexate (31.4%). Use of methotrexate has increased 17-fold (1.8% of all DMARD prescriptions in 1988 to 30% in 2002) whereas use of gold has fallen (13.2% to 2.3%). Analysis of DMARD persistence using Kaplan-Meier survival curves showed the methotrexate use persisted significantly longer than other DMARDs with an estimated median of 8.1 yr. Prednisolone was used in up to 50% of RA patients in any one year and has remained fairly constant throughout the study period. CONCLUSIONS Large numbers of individuals with a clinical diagnosis of RA identified from a large primary care database are not receiving DMARDs. This work suggests that many individuals with RA have not been treated appropriately and this may have major long-term consequences on joint damage and general health.

[1]  Jerzy Swierkot,et al.  Methotrexate in rheumatoid arthritis. , 2006, Pharmacological reports : PR.

[2]  G. Newsome.  Guidelines for the management of rheumatoid arthritis: 2002 update. , 2002, Journal of the American Academy of Nurse Practitioners.

[3]  A. Silman,et al.  The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. , 2002, Rheumatology.

[4]  James M Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[5]  W. Bilker,et al.  Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease , 2002, Pharmacoepidemiology and drug safety.

[6]  R. Yood,et al.  Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.

[7]  J. Wong,et al.  Long-term morbidity, mortality, and economics of rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[8]  C. Cooper,et al.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.

[9]  L Abenhaim,et al.  The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results , 2000, Pharmacoepidemiology and drug safety.

[10]  L. Criswell,et al.  Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. , 1997, The Journal of rheumatology.

[11]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[12]  R. Rau,et al.  Long-term treatment of destructive rheumatoid arthritis with methotrexate. , 1997, The Journal of rheumatology.

[13]  M. Picot,et al.  Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. , 1997, British journal of rheumatology.

[14]  A. Silman,et al.  A comparison of disease status in rheumatoid arthritis patients attending and not attending a specialist clinic. , 1996, British journal of rheumatology.

[15]  A. Silman,et al.  Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. , 1996, The Journal of rheumatology.

[16]  G. Alarcón,et al.  Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. , 1995, Annals of the rheumatic diseases.

[17]  R. Mann,et al.  The VAMP Research multi-purpose database in the U.K. , 1995, Journal of clinical epidemiology.

[18]  A. Silman,et al.  The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. , 1994, British journal of rheumatology.

[19]  A M Walker,et al.  The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[20]  T. Pincus,et al.  Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. , 1992, The Journal of rheumatology.

[21]  J. Kremer,et al.  Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. , 1992, Arthritis and rheumatism.

[22]  M. Weinblatt,et al.  Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. , 1992, Arthritis and rheumatism.

[23]  G. Hall.  Pharmacoepidemiology using a UK database of primary care records , 1992 .

[24]  F. Wolfe,et al.  Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. , 1990, The Journal of rheumatology.

[25]  J. Stross.  Relationships between knowledge and experience in the use of disease-modifying antirheumatic agents. A study of primary care practitioners. , 1989, JAMA.

[26]  G. Alarcón,et al.  Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. , 1989, Arthritis and rheumatism.